19:07 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest dual FPR1/FPRL1 agonists could help treat MI. In primary rat and mouse cardiomyocyte-based models of ischemia/reperfusion, a dual FPR1/FPRL1 agonist tool compound decreased levels of the cardiomyocyte injury marker...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Formyl peptide receptor-like 1 (FPRL1; FPR2) Cell culture studies suggest agonizing FPR2 in innate immune cells...
08:00 , Feb 18, 2013 |  BioCentury  |  Emerging Company Profile

Signum: Rosacea double play

Therapies on the market or in development for rosacea treat either the symptomatic flushing or the inflammatory skin lesions. Signum Dermalogix Inc.'s lead small molecule isoprenylcysteine analog could treat both aspects of rosacea by targeting...
08:00 , Dec 20, 2012 |  BC Innovations  |  Strategy

MRC Technology extends reach

After six years of focusing on developing small molecule drug candidates and humanizing therapeutic mAbs, both mostly from U.K. source, MRC Technology, the commercialization arm of the country's Medical Research Council, is taking its search...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

BioLineRx, Compugen deal

BioLineRx and Compugen partnered to develop products to treat diseases including acute and chronic inflammatory diseases, cardiac diseases, retinopathy and cancer. Compugen will grant BioLineRx exclusive, worldwide rights to products, primarily peptides, identified using Compugen's...
08:00 , Mar 5, 2007 |  BioCentury  |  Tools & Techniques

Predicting active peptides

Compugen Ltd. says it has developed an in silico discovery engine for peptides that bind GPCRs. So far, the engine has yielded eight peptides with dose-dependent activity, and CGEN plans to advance two into preclinical...